who we are

doctors specializing
in biologics in kansas city

Motus evaluates your specific orthopedic injury or disease and provides you with customized/individualized/personalized plan of care. Whether that be physical therapy, biologics, Tenex, or even surgery. Motus is here to ensure you are aware of the options available to you. Motus offers nonsurgical treatment options as opposed to traditional surgical interventions. This includes biologics which uses the patient’s own stem cells and platelet-rich plasma to stimulate regrowth of their own tissues instead of having these tissues surgically replaced or removed.

A profile of
Dr. Leslie Michaud

background

history, education, and residency

I am originally from the Chicagoland area and I attended medical school at the University of Illinois at Chicago. I completed my internship and residency in family medicine from the Mayo Clinic in Rochester, Minnesota. After residency, I practiced family medicine in both the hospital and clinic setting as well as occupational and student health. I found myself drawn to orthopedic conditions and decided to further my career with fellowship training in primary care sports medicine at the Steadman Hawkins Clinic of the Carolinas.

specialty

Why did you decide to specialize in sports medicine and biologics?

Most young physicians in the orthopedic field have a very broad understanding of the use of biologics. So it was something I was always aware of but I hadn’t necessarily been exposed to.

An orthopedic device rep told me about a practice in Columbia and St. Louis called Bluetail Medical Group that was exclusively using biologics in the treatment of cartilage, joint, tendon, ligament, and bone conditions for the past 12 years. I decided to visit their practice and see first hand what the procedures encompassed and to learn about outcomes from the patient’s themselves.

What I saw left me in awe. Not only were patients experiencing amazing outcomes, but they were avoiding traditional surgical interventions for which they were either not interested in or were not a candidate for. Biologics is an option to offer patients that aligns with my own personal philosophy of starting with more noninvasive interventions and progressing if necessary.

What’s next

What can patients expect in the future from your practice?

Patients can expect Motus to continually offer the most advanced biologic treatments for orthopedic conditions. We are committed is to stay up to speed with emerging research and to be leaders in facilitating new advancements. If you choose to proceed with a treatment, we will ask for your permission to be part of a research study to track your progress. The patient is an integral part of the advancement process.

Purpose

why biologics?

Because I believe in choices. Motus is here to provide evaluation and personalized treatment plans. Mastering and advancing biologics gives patient’s another option to treat their orthopedic conditions. In more cases than not, the body knows how to heal itself. Motus is using the patient’s own stem cells and platelet-rich plasma to stimulate regrowth of their own tissues instead of having these tissues surgically replaced or removed. These healing factors can’t get there on their own so we’re basically “cheating” by taking them and putting them where they belong. In comparison to traditional surgical interventions, biologics is cheaper, far less risky, and requires less recovery time.

drive

What is your motivation to continue & improve your practice?

Practicing status quo techniques in medicine is not what I call leadership. The current state of healthcare in our country is in desperate need of disruption. We need to find innovate solutions to emerging issues. Using the same narrative and dead-end thinking is NOT working.

Our 65 and older population is going to increase 78% in the next 25 years. This means more folks with arthritis and degenerative orthopedic conditions. Not everyone is a candidate for replacement surgery and some people simply don’t want to have a replacement. In addition, over one-third of our population is obese and this puts them at greater postoperative risk for certain complications. Then there’s the increasing number of active individuals who don’t want to be down for 3 months in the face of injury.

There is more evidence supporting the use of biologics alongside surgical intervention to improve outcomes and healing times. Changes in our population and subsequent challenges motivate me to find new solutions for my patients. Patients deserve options and autonomy when it comes to their bodies. That’s what motivates me.